Inventiva (NASDAQ:IVA) Stock Price Up 10.8% – Here’s What Happened

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price was up 10.8% during mid-day trading on Monday . The company traded as high as $5.83 and last traded at $5.9480. Approximately 58,752 shares traded hands during trading, a decline of 86% from the average daily volume of 422,250 shares. The stock had previously closed at $5.37.

Analyst Ratings Changes

A number of equities research analysts have issued reports on IVA shares. Barclays started coverage on shares of Inventiva in a research note on Tuesday, January 27th. They set an “overweight” rating and a $18.00 target price for the company. Truist Financial started coverage on shares of Inventiva in a research note on Thursday, March 19th. They set a “buy” rating and a $13.00 target price for the company. Leerink Partners started coverage on shares of Inventiva in a research note on Monday, January 12th. They set an “outperform” rating and a $12.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Finally, Wall Street Zen lowered shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Inventiva has a consensus rating of “Buy” and a consensus price target of $16.56.

Inventiva Stock Performance

The business’s 50 day simple moving average is $5.74 and its 200-day simple moving average is $5.34.

Inventiva (NASDAQ:IVA) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $0.01 million for the quarter. Equities research analysts expect that Inventiva S.A. Sponsored ADR will post -0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC bought a new position in shares of Inventiva during the 4th quarter valued at $60,000. ADAR1 Capital Management LLC bought a new position in shares of Inventiva during the 4th quarter valued at $12,601,000. XTX Topco Ltd bought a new position in shares of Inventiva during the 4th quarter valued at $84,000. Yu Fan bought a new position in shares of Inventiva during the 4th quarter valued at $6,975,000. Finally, Ikarian Capital LLC bought a new position in Inventiva in the 4th quarter worth $2,329,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.